Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

PD Controller: Design

PD Controller: Design

In automotive engineering, car suspension systems often employ Proportional Derivative (PD) controllers to enhance performance. PD controllers are utilized to adjust the damping force in response to road conditions. A controller, acting as an amplifier with a constant gain, demonstrates proportional control, with output directly mirroring input.
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...

Time-Domain Interpretation of PD Control

Time-Domain Interpretation of PD Control

Proportional-Derivative (PD) control is a widely used control method in various engineering systems to enhance stability and performance. In a system with only proportional control, common issues include high maximum overshoot and oscillation, observed in both the error signal and its rate of change. This behavior can be divided into three distinct phases: initial overshoot, subsequent undershoot, and gradual stabilization.
Consider the example of control of motor torque. Initially, a positive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026

Same author

Dietary reprogramming of T-cell function enhances anti-cancer immunotherapy efficacy.

Journal of hepatology·2026

Same author

The 2024 International Liver Transplant Society and International Liver Cancer Association Consensus Recommendations for Liver Transplantation for Liver Cancer.

Liver cancer·2026

Same author

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.

Journal of hepatology·2026

Same author

A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms.

British journal of cancer·2026

Same author

Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours.

European journal of cancer (Oxford, England : 1990)·2026

Same journal

Defining biochemical, pathological and molecular factors prognostic in terms of disease control and survival in high-grade extremity soft tissue sarcoma: a scoping review.

Journal of clinical pathology·2026

Same journal

MILGDF: a multi-task, instance-level supervised model for oral squamous cell carcinoma integrating local-global attention and dynamic decision fusion.

Journal of clinical pathology·2026

Same journal

Paediatric B-lymphoblastic leukaemia with low peripheral blasts: a potential diagnostic pitfall.

Journal of clinical pathology·2026

Same journal

MRI-targeted versus systematic needle core biopsies in prostate cancer: a patient-based analysis of potential diagnostic and biologic underestimation.

Journal of clinical pathology·2026

Same journal

Basal plasmacytosis and eosinophilia for distinguishing inflammatory bowel disease from gastrointestinal tuberculosis on mucosal biopsy.

Journal of clinical pathology·2026

Same journal

Assay-dependent variability in free thyroxine (FT4): differential interference related to immunoassay design in a patient with subclinical hypothyroidism.

Journal of clinical pathology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

PD-L1.

Anthousa Kythreotou¹, Abdul Siddique¹, Francesco A Mauri¹

¹Departmentof Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK.

Journal of Clinical Pathology

|November 4, 2017

Summary

This summary is machine-generated.

Programmed death ligand 1 (PD-L1) is crucial for immune tolerance but exploited by cancers for immune evasion. Its role as a predictive biomarker for anti-PD-1/PD-L1 therapies is complex and warrants further investigation.

Keywords:

cancer immunology oncogenes

More Related Videos

Author Spotlight: Microscopic Analysis of Protein Localization at Plasmodesmata in Plants

Author Spotlight: Microscopic Analysis of Protein Localization at Plasmodesmata in Plants

Published on: November 1, 2024

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Experiment Videos

Last Updated: Feb 19, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Author Spotlight: Microscopic Analysis of Protein Localization at Plasmodesmata in Plants

Author Spotlight: Microscopic Analysis of Protein Localization at Plasmodesmata in Plants

Published on: November 1, 2024

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Area of Science:

Immunology
Oncology
Molecular Biology

Background:

Programmed death ligand 1 (PD-L1) interacts with programmed death 1 (PD-1), a receptor vital for immune tolerance.
PD-L1 expression in cancer serves as an immune evasion mechanism, often correlating with poor prognosis.
The PD-1/PD-L1 pathway plays a dual role in regulating immune responses and preventing autoimmunity.

Purpose of the Study:

To review the immunobiology of PD-L1.
To explore the clinical significance of PD-L1 in malignancy.
To discuss PD-L1's role as a predictive biomarker for anti-PD-1/PD-L1 therapies.

Main Methods:

Literature review of PD-L1 immunobiology.
Analysis of clinical significance of PD-L1 in various cancers.
Evaluation of PD-L1 as a predictive biomarker for immunotherapy response.

Main Results:

PD-L1 is expressed in various cell types, including cancer cells.
PD-L1 expression is linked to immune evasion and poorer prognosis in malignancies.
Evidence regarding PD-L1's predictive value for anti-PD-1/PD-L1 therapy response is contradictory across different histotypes.

Conclusions:

Understanding PD-L1's complex role is essential for optimizing cancer immunotherapy.
Further research is needed to clarify PD-L1's utility as a predictive biomarker across diverse malignancies.
Anti-PD-1/PD-L1 therapies show promise in treating various cancers, including metastatic lung cancer and melanoma.